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Concise Report
Depression in RA patients treated with anti-TNF is common and
under-recognized in the rheumatology clinic
Samantha L. Hider1,2, Wajeeha Tanveer1, Ann Brownfield1, Derek L. Mattey1 and Jon C. Packham1,2
Objectives. Depression is common in RA and may be influenced by both disease activity and severity. The aims of this study were to
investigate the prevalence of depression in RA patients starting anti-TNF therapy, to investigate how mood alters after exposure to anti-TNF
and to determine whether depression is recognized and appropriately managed in the clinic.
Methods. Patients starting anti-TNF therapy were assessed for depression using the Hospital Anxiety and Depression Scale (HADS-D), and
classified as depressed with an HADS-D of58. Change in mood was assessed at 6 weeks, 4 months and 12 months. Disease activity data
were recorded at baseline, 3 and 12 months. Patients who remained persistently depressed at 4 months had their clinical case notes
reviewed to determine whether their low mood had been recognized or treated.
Results. Depression was common in this cohort. Depressed patients had higher disease activity scores (DAS28) at all time points, and
patients with persistent depression had smaller reductions in DAS28 [median (interquartile range or IQR) change DAS28 1.71 (0–2.6) vs 2.2
(1.5–3.2); P¼ 0.005]. Only 57% (13/23) patients with persistent depression at 4 months had their depression recognized or managed within
the rheumatology clinic.
Conclusions. Depression is common but under-recognized in RA patients starting on anti-TNF therapy. Patients with persistent depression
tended to respond less well to anti-TNF, with smaller reductions in DAS28. Given that a significant reduction in DAS28 is a requirement for
continuing therapy, recognition and appropriate management of depression may improve TNF effectiveness.
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Introduction
RA and depression commonly co-exist with conservative estimates
of the prevalence of depression in RA between 13 and 20% [1–3].
Prevalence of depression in RA is related to several factors includ-
ing pain, physical disability [4] and comorbidity [5], and is highest
among those with the most severe disease. Data from the
UK biologics registry suggested that 19% of those commencing
anti-TNF therapy had a diagnosis of depression at some time in
their disease course [6].
Importantly, depression may influence both reporting of symp-
toms and response to medication. Studies show that the HAQ
score, the most frequently used measure of physical disability, is
strongly influenced by depression [7] and pain reporting is similarly
influenced [2]. Comorbid depression increases both work disability
[8] and mortality in RA [9]. In addition, depression may influence
response to treatment both in RA [10] and in FM [11].
Thus, comorbid depression is common and negatively influ-
ences disease course and treatment outcome. This study was
undertaken to investigate whether depression was recognized
and appropriately treated within the routine rheumatology clinic
in a cohort of patients with severe RA starting on anti-TNF
therapy.
Patients and methods
Subjects
Patients were recruited from the anti-TNF clinic at the
Staffordshire Rheumatology Centre, a large secondary
care centre. All patients starting anti-TNF therapy for RA
between 2002 and 2006, satisfying ARA criteria for RA [12],
were eligible to be included in the study. Patients were assessed
for depression using the Hospital Anxiety and Depression Scale
(HADS) [13]. Patients were classified as having probable depres-
sion if they had an HADS depression score (HADS-D) of 58,
and severe depression if they had an HADS-D of511. Change in
mood using the HAD was assessed at 6 weeks, 4 and 12 months.
Patients were classified as persistently depressed if they had an
HADS-D score of 58 at baseline and on a second occasion in
the first 4 months. Data on disease activity, including components
of the disease activity score (DAS28) [14], were recorded at base-
line, 3 and 12 months. Patients who were withdrawn from anti-
TNF for any reason during the study were excluded from further
follow-up. Patient’s written consent was obtained according to the
Declaration of Helsinki, and the study was approved by the North
Staffordshire local research ethics committee.
To determine whether depression was recognized and appro-
priately managed within the routine rheumatology clinic, patients
who remained persistently depressed at 4 months had their clinical
case notes reviewed to determine whether their low mood
had been recognized and/or managed with either anti-depressant
therapy or onward referral. This cut-off of 4 months for persistent
depression was deliberately chosen as we hypothesized that if anti-
TNF therapy is effective and leads to an improvement in disease
activity and pain, there may be an associated improvement in
mood and, therefore, we did not wish to be prematurely treating
patients with low mood who may have improved without addi-
tional management.
Statistical analysis
Differences in the clinical variables between depressed and non-
depressed patients were investigated using the Wilcoxon–Mann–
Whitney test for continuous variables. Data are presented as
median [interquartile range (IQR)] unless otherwise stated.
All analyses were performed using STATA 8.
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Results
Patient characteristics and prevalence of depression
Of 160 potentially eligible patients, 159 were eligible for the study.
This was a typical cohort of anti-TNF patients with severe long-
standing RA, mean (S.D.) disease duration of 13.6 (8.7) years.
Within the cohort, 72% were female, with a mean (S.D). age of
56.4 (12.18) years, and 76% of the patients were RF positive.
Depression occurred frequently in this cohort, with 76/160
(47.5%) classified as depressed at baseline. The proportion of
patients continuing on anti-TNF therapy was 156/159 (98%) at
6 weeks, 138/159 (87%) at 4 months and 122/159 (77%) at
12 months. The percentage of patients completing the HAD was
114/156 (73%) at 6 weeks, 106/138 (77%) at 4 months and 82/122
(67%) at 12 months. The proportion of patients continuing
anti-TNF but remained depressed fell to 24% at 6 weeks, 19%
at 4 months and 15% at 12 months. The development of new
depression following anti-TNF exposure was uncommon; only
five patients were subsequently classified as depressed over the
next 12 months.
Effect of persistent depression on disease activity
Subjects who were classified as depressed at baseline had higher
DAS28 scores than those who were not depressed at baseline at
all time points (Table 1), although this difference was no longer
statistically significant at 12 months. Evaluating the DAS28 scores
at 3 months of those remaining on anti-TNF (n¼ 138), in those
subjects with persistent depression, the reduction in DAS28 at
3 months was lower than in those without persistent depression
[median (IQR) change DAS28 1.71 (0–2.6) vs 2.2 (1.5–3.2);
P¼ 0.005], indicating that the anti-TNF therapy had a less bene-
ficial impact on their disease activity measures. This difference was
due to effects on both objective measures of inflammation
[swollen joint count (SJC) persistent depressed vs non-depressed,
7 vs 4; P¼ 0.006] and more subjective measures (or potentially
influenced by mood) such as the tender joint count (TJC) (persis-
tent depressed vs non-depressed, 9 vs 5; P¼ 0.001), and was
despite having similar disease activity at baseline. These results
are summarized in Table 2.
Management of persistent depression in the routine clinic
Of the 23 patients with persistent depression at 4 months, depres-
sion had been recognized and treatment initiated before the start
of anti-TNF in nine (39%) patients. Further, four (17%) patients
received treatment for depression following anti-TNF initiation.
However, 10/23 (43%) patients did not have their depression
recognized or treated during the follow-up. Three (30%) of
these patients with unrecognized depression had an HADS-D
score of 511 at baseline, suggesting severe depression. The
majority of those patients receiving treatment for depression was
prescribed anti-depressants although 6/23 (26%) were also
referred to a liaison psychiatry clinic for further assessment.
Discussion
Co-existent depression is common in RA and is more frequent
with both worsening disease activity and severity. As expected,
in this cohort of patients with severe disease starting anti-TNF
treatment, co-existent depression was common. The prevalence of
depression in our cohort was higher than that reported by Hyrich
et al. [6]. Only a small proportion of non-depressed patients at
baseline subsequently developed depression following exposure to
anti-TNF therapies. This suggests that anti-TNF does not have
significant adverse effects on mood in RA.
Patients who were classified as depressed had higher DAS28
scores than those not depressed, although it is of note that both
objective measures (such as SJC) and potentially subjective mea-
sures (such as TJC) were higher in depressed patients. In addition,
patients who exhibited persistent depression had poorer responses
to anti-TNF therapy at 3 months, with smaller reductions in
DAS28 score. Given that an adequate reduction in DAS28 is a
pre-requisite for continuing with anti-TNF therapy, this suggests
that depressed patients, particularly those whose depression is
persistent, may be more at risk of having their treatment
deemed ineffective than those not depressed.
Depression was generally poorly recognized within the routine
rheumatology clinic with 10/23 (43%) of those patients with
persistent depression not having their depression recognized or
treated. This is despite frequent outpatient attendances by all
patients as they were started on new therapeutic regimes. Given
that depression is eminently treatable, with studies suggesting that
70% of the patients respond to first-line treatment with anti-
depressants [15, 16], these results are disappointing and represent
a missed opportunity to improve care for these patients. However,
given that studies suggest only 30–50% of the general population
with depression receive appropriate intervention [17], and we
studied patients with severe and active RA for whom the focus
of the consultation would not have been mood disturbance, our
results are perhaps not surprising. We included all patients with an
HAD-D of58 in the analysis, including those who had treatment
initiated for depression before commencing anti-TNF, as they
had failed to respond adequately to anti-depressant therapy as
indicated by an HAD-D of 58.
There are a number of strengths and weaknesses that need to be
considered when interpreting the results of this study. All RA
patients starting anti-TNF therapy were included in the study
and thus results should be generalizable to other large secondary
care urban rheumatology centres. Data were collected during the
time period that anti-TNF was introduced to the UK. This inevi-
tably means that a severely affected group of historical non-
responders to DMARDs are included within this cohort. These
patients tend to have severe RA and may have higher levels of
physical functional loss, disease activity and depression. This
should not influence the overall findings of this study, but may
have increased the levels of disease activity and depression
described within the cohort.
Patients were characterized as depressed if they had an HAD-D
score of58. Although a diagnosis of depression can only be made
on the basis of a diagnostic interview, studies suggest that using an
HAD-D cut-off of 58 to identify depression compares well with
the gold standard of a diagnostic interview, with a sensitivity and
specificity of around 0.8 [18]. In addition, patients completed the
HAD questionnaires at different time points to their clinical
reviews, disease activity and DAS28 assessments to attempt to
reduce any direct effects of clinician contact on mood.
TABLE 1. Effect of baseline depression on the DAS28 and HAD-D score
Baseline depressed,
median (IQR)
Baseline not-depressed,
median (IQR) P-value
Mean S.D.
change from
baseline depressed
Mean S.D.
change from
baseline not-depressed P-value
HADS-D baseline 11 (9–13) 5 (3–6) 0.0001
HADS-D 6 weeks 8 (5–11) 3 (1–5) 0.0001 2.93.75 12.6 0.004
HADS-D 4 months 8 (4–11) 4 (1–5) 0.0001 3.24.58 1.112.8 0.01
HADS-D 12 months 8 (3–9) 2 (1–4) 0.0001 3.753.95 1.492.4 0.01
DAS28 baseline 7.2 (6.5–7.8) 6.7 (5.9–7.4) 0.005
DAS28 3 months 5.0 (3.9–6.4) 4.5 (3.7–5.3) 0.02 1.931.38 2.11.2 0.32
DAS28 12 months 5.5 (4.8–6.3) 4.5 (3.1–5.6) 0.42 21.37 1.951.69 0.85
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Because treatment for depression was determined by the review
of secondary care case notes, it is possible that some patients may
have received treatment for depression, initiated in primary care,
but not recorded in the secondary care. However, patients were
specifically asked to report any change in medication at each clinic
attendance, and subsequent under-reporting of anti-depressant
initiation is unlikely to have significantly influenced our findings.
In summary, depression is common in patients starting anti-
TNF therapy and tends to improve after anti-TNF exposure.
However, depression is significantly under-recognized and treated
within the rheumatology clinic. Given that depression is treatable
and is associated with poorer responses to anti-TNF, recognition
and appropriate management of depression may improve TNF
effectiveness.
Rheumatology key messages
 Persistent depression is poorly recognized and managed in
routine rheumatology clinics.
 Patients with persistent depression have a poorer response to
anti-TNF therapy.
 Appropriate management of depression may improve effective-
ness of anti-TNF.
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TABLE 2. Effect of persistent depression on disease activity
Persistent depression No persistent depression P-value
Baseline
28-TJC 18 (11–24) 17 (11–24) 0.76
28-SJC 13 (10–180 11 (8–16) 0.1
ESR 52 (38–64) 46 (32–70) 0.35
CRP 59 (27–91) 45 (23–65) 0.16
PGA 72 (60–89) 77 (68–86) 0.5
DAS28 7.1 (6.43–7.82) 6.8 (6.06–7.58) 0.09
3 months
28-TJC 9 (4–19) 5 (2–8) 0.001
28-SJC 7 (4–11) 4 (2–7) 0.006
ESR 39 (20–62) 27 (12–43) 0.08
CRP 22 (9–60) 12 (5–37) 0.045
PGA 35 (22–62) 29 (17–45) 0.3
DAS28 5.8 (4.4–6.7) 4.4 (3.5–5.3) 0.001
Change DAS28 1.7 (0–2.6) 2.2 (1.5–3.2) 0.005
Results are expressed as median (IQR).
1154 Samantha L. Hider et al.
 by guest on M
arch 19, 2013
http://rheum
atology.oxfordjournals.org/
D
ow
nloaded from
 
